[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.0.26. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
April 1982

Clinical Use of Thrombolytic Agents in Venous Thromboembolism

Author Affiliations

From the Medical (Drs Sasahara, Sharma, McIntyre, and Parisi), Nuclear Medicine (Dr Tow), and Research (Dr Cella) Services, West Roxbury (Mass) Veterans Administration Medical Center; and the Departments of Medicine (Drs Sasahara, Sharma, McIntyre, Parisi, and Cella) and Nuclear Medicine (Dr Tow), Brigham and Women's Hospital and Harvard Medical School, Boston.

Arch Intern Med. 1982;142(4):684-688. doi:10.1001/archinte.1982.00340170040008
Abstract

• The use of thrombolytic agents in venous thromboembolism has been shown to be highly effective. Patients treated with lytic agents show more rapid clot resolution and lung reperfusion and more rapid and greater reversal of the abnormal hemodynamic responses to pulmonary embolism than patients receiving heparin. Moreover, lytic therapy removes thromboemboli more completely from the pulmonary microcirculation, whereas residual thromboemboli tend to accumulate with heparin therapy. In addition, lytic therapy tends to preserve the venous valves, whereas distortion and destruction occur with heparin therapy. Hence, lytic therapy confers a number of short- and long-term benefits not observed with heparin therapy.

(Arch Intern Med 1982;142:684-688)

×